Top ▲
Target id: 2076
Nomenclature: mitogen-activated protein kinase kinase kinase 19
Abbreviated Name: YSK4
Family: STE20 subfamily
Gene and Protein Information | ||||||
Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
Human | - | 1328 | 2q21.3 | MAP3K19 | mitogen-activated protein kinase kinase kinase 19 | |
Mouse | - | 1311 | 1 E3 | Map3k19 | mitogen-activated protein kinase kinase kinase 19 | |
Rat | - | 1306 | 13q12 | Map3k19 | mitogen-activated protein kinase kinase kinase 19 |
Previous and Unofficial Names |
RCK | Regulated in COPD, protein kinase | Sps1/Ste20-related protein kinase YSK4 |
Database Links | |
Alphafold | Q56UN5 (Hs), E9Q3S4 (Mm) |
BRENDA | 2.7.11.1 |
ChEMBL Target | CHEMBL6191 (Hs) |
Ensembl Gene | ENSG00000176601 (Hs), ENSMUSG00000051590 (Mm), ENSRNOG00000003952 (Rn) |
Entrez Gene | 80122 (Hs), 22625 (Mm), 289001 (Rn) |
Human Protein Atlas | ENSG00000176601 (Hs) |
KEGG Enzyme | 2.7.11.1 |
KEGG Gene | hsa:80122 (Hs), mmu:22625 (Mm), rno:289001 (Rn) |
Pharos | Q56UN5 (Hs) |
RefSeq Nucleotide | NM_025052 (Hs), NM_011737 (Mm), XM_002727999 (Rn) |
RefSeq Protein | NP_079328 (Hs), NP_035867 (Mm), XP_002728045 (Rn) |
UniProtKB | Q56UN5 (Hs), E9Q3S4 (Mm) |
Wikipedia | MAP3K19 (Hs) |
Enzyme Reaction | ||||
|
Download all structure-activity data for this target as a CSV file
Inhibitors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | View all chemical structures | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inhibitor Comments | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
MAP3K19 activity is inhibited by approximately 96% in the presence of 1μM compound 1 [PMID 24793884] [5] (note that MAP3K19 is referred to by its synonym YSK4 in the article's Supplementary data table).. |
DiscoveRx KINOMEscan® screen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
A screen of 72 inhibitors against 456 human kinases. Quantitative data were derived using DiscoveRx KINOMEscan® platform. http://www.discoverx.com/services/drug-discovery-development-services/kinase-profiling/kinomescan Reference: 3,6 |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Target used in screen: YSK4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Displaying the top 10 most potent ligands View all ligands in screen » |
Immunopharmacology Comments |
MAP3K19 is expressed predominantly by alveolar and interstitial macrophages and bronchial epithelial cells in the lung and is overexpressed in chronic obstructive pulmonary disease (COPD) [2], and regulates TGF-β signaling in experimental models of lung injury and pulmonary fibrosis [1]. |
Cell Type Associations | ||||||
|
1. Boehme SA, Franz-Bacon K, DiTirro DN, Ly TW, Bacon KB. (2016) MAP3K19 Is a Novel Regulator of TGF-β Signaling That Impacts Bleomycin-Induced Lung Injury and Pulmonary Fibrosis. PLoS ONE, 11 (5): e0154874. [PMID:27144281]
2. Boehme SA, Franz-Bacon K, Ludka J, DiTirro DN, Ly TW, Bacon KB. (2016) MAP3K19 Is Overexpressed in COPD and Is a Central Mediator of Cigarette Smoke-Induced Pulmonary Inflammation and Lower Airway Destruction. PLoS ONE, 11 (12): e0167169. [PMID:27935962]
3. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP. (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol, 29 (11): 1046-51. [PMID:22037378]
4. Ma B, Bohnert T, Otipoby KL, Tien E, Arefayene M, Bai J, Bajrami B, Bame E, Chan TR, Humora M et al.. (2020) Discovery of BIIB068: A Selective, Potent, Reversible Bruton's Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases. J Med Chem, 63 (21): 12526-12541. [PMID:32696648]
5. Reichelt A, Bailis JM, Bartberger MD, Yao G, Shu H, Kaller MR, Allen JG, Weidner MF, Keegan KS, Dao JH. (2014) Synthesis and structure-activity relationship of trisubstituted thiazoles as Cdc7 kinase inhibitors. Eur J Med Chem, 80: 364-82. [PMID:24793884]
6. Wodicka LM, Ciceri P, Davis MI, Hunt JP, Floyd M, Salerno S, Hua XH, Ford JM, Armstrong RC, Zarrinkar PP et al.. (2010) Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. Chem Biol, 17 (11): 1241-9. [PMID:21095574]
STE20 subfamily: mitogen-activated protein kinase kinase kinase 19. Last modified on 12/08/2020. Accessed on 10/10/2024. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetomalariapharmacology.org/GRAC/ObjectDisplayForward?objectId=2076.